<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005025</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067546</org_study_id>
    <secondary_id>HGTRI-0105</secondary_id>
    <secondary_id>NCI-V00-1584</secondary_id>
    <nct_id>NCT00005025</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Stoddard Cancer Center at Iowa Methodist Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have&#xD;
      refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy and safety of in vivo gene therapy with herpes simplex thymidine&#xD;
           kinase (HSVtk) vector producer cells (VPC) followed by ganciclovir in women with&#xD;
           refractory or relapsed ovarian epithelial adenocarcinoma, fallopian tube cancer, or&#xD;
           peritoneal cancer.&#xD;
&#xD;
        -  Determine any development of systemic immunity to this regimen or tumor in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the toxic effects of intraperitoneal HSVtk VPC in these patients.&#xD;
&#xD;
      OUTLINE: All patients receive an intraperitoneal catheter prior to infusion.&#xD;
&#xD;
      Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over&#xD;
      15-60 minutes on day 0, followed by ganciclovir IV 2 times daily on days 28-41. Treatment&#xD;
      repeats for up to 3 courses in patients with stable or responsive disease.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-20 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>herpes simplex thymidine kinase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma,&#xD;
             fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy&#xD;
             exists&#xD;
&#xD;
               -  Must have tissue available from tumor biopsy to grow tumor cells ex vivo&#xD;
&#xD;
               -  Must have failed standard therapy with both a platinum agent (cisplatin or&#xD;
                  carboplatin) and paclitaxel&#xD;
&#xD;
          -  Site of disease must be less than 5 cm in greatest diameter&#xD;
&#xD;
          -  Evaluable disease by CT scan, physical exam, or laparoscopy&#xD;
&#xD;
          -  No significant peritoneal fibrosis either from disease or prior surgery&#xD;
&#xD;
               -  Surgical lysis of adhesions allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 2,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL (without transfusion)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT no greater than 4 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 4 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen test required prior to study if transaminases greater than&#xD;
             2.0 times ULN&#xD;
&#xD;
          -  No hepatitis B surface antigen&#xD;
&#xD;
          -  Amylase normal&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac dysfunction by history and exam&#xD;
&#xD;
          -  No ischemic heart disease that may be considered anesthetic or operative risk&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No lung disease that may be considered anesthetic or operative risk&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No acute viral, bacterial, or fungal infection requiring medication within 14 days&#xD;
             prior to study&#xD;
&#xD;
          -  No patient with greater than 2 L of ascites at the time of intraperitoneal infusion&#xD;
&#xD;
          -  No underlying condition that would preclude compliance&#xD;
&#xD;
          -  No allergies to study reagent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent high dose vitamin regimens&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Joseph Link, MD</last_name>
    <role>Study Chair</role>
    <affiliation>John Stoddard Cancer Center at Iowa Methodist Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Gene Therapy Research Institute</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

